Vanguard Group
TSHA icon

Vanguard Group’s Taysha Gene Therapies TSHA Stock Holding History

Vanguard Group’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$73M Buy
13,267,805
+418,192
+3% +$2.03M ﹤0.01% 1990
2025
Q3 		$42M Buy
12,849,613
+1,955,486
+18% +$5.54M ﹤0.01% 2248
2025
Q2 		$25.2M Buy
10,894,127
+2,123,206
+24% +$4.61M ﹤0.01% 2458
2025
Q1 		$12.2M Sell
8,770,921
-135,843
-2% -$227K ﹤0.01% 2740
2024
Q4 		$15.4M Buy
8,906,764
+641,305
+8% +$1.33M ﹤0.01% 2721
2024
Q3 		$16.6M Buy
8,265,459
+1,098,122
+15% +$2.41M ﹤0.01% 2682
2024
Q2 		$16.1M Buy
7,167,337
+1,249,923
+21% +$3.64M ﹤0.01% 2672
2024
Q1 		$17M Sell
5,917,414
-278,153
-4% -$580K ﹤0.01% 2680
2023
Q4 		$11M Buy
6,195,567
+867,703
+16% +$1.73M ﹤0.01% 2896
2023
Q3 		$16.8M Buy
5,327,864
+3,738,616
+235% +$6.98M ﹤0.01% 2614
2023
Q2 		$1.05M Buy
1,589,248
+5,810
+0.4% +$4.21K ﹤0.01% 3881
2023
Q1 		$1.26M Buy
1,583,438
+27,772
+2% +$35.9K ﹤0.01% 3847
2022
Q4 		$3.52M Buy
1,555,666
+484,864
+45% +$982K ﹤0.01% 3454
2022
Q3 		$2.07M Hold
1,070,802
– – ﹤0.01% 3728
2022
Q2 		$3.98M Buy
1,070,802
+58,638
+6% +$233K ﹤0.01% 3497
2022
Q1 		$6.6M Buy
1,012,164
+128,517
+15% +$961K ﹤0.01% 3377
2021
Q4 		$10.3M Buy
883,647
+77,929
+10% +$1.18M ﹤0.01% 3186
2021
Q3 		$15M Buy
805,718
+177,074
+28% +$3.37M ﹤0.01% 3014
2021
Q2 		$13.3M Buy
628,644
+168,396
+37% +$3.88M ﹤0.01% 3056
2021
Q1 		$9.34M Sell
460,248
-4,602
-1% -$125K ﹤0.01% 3183
2020
Q4 		$12.3M Buy
464,850
+389,850
+520% +$8.4M ﹤0.01% 2884
2020
Q3 		$1.68M Buy
+75,000
New +$1.76M ﹤0.01% 3534

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Vanguard Group's TSHA Position: Q4 2025 in Review

Vanguard Group increased its Taysha Gene Therapies (TSHA) stake by 3.3% in Q4 2025, buying an estimated $2.03M and bringing the position to 13,267,805 shares worth $73M. The position accounts for ﹤0.01% of the portfolio, ranked #1990.

Vanguard Group first reported a position in TSHA in Q3 2020 and has held it in 22 quarters since. 195 funds tracked by Wall St. Rank hold TSHA as of Q4 2025.

  • Vanguard Group held 13,267,805 shares of Taysha Gene Therapies worth $73M as of Q4 2025.
  • Vanguard Group bought 418,192 Taysha Gene Therapies shares in Q4 2025, an estimated $2.03M.
  • Taysha Gene Therapies made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1990 holding.
  • Vanguard Group first reported a position in Taysha Gene Therapies in Q3 2020 and has held it in 22 quarters since.
  • 195 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.